+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Infectious Vaccines Market by Vaccine Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674944
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Vaccines Market grew from USD 31.83 billion in 2024 to USD 34.88 billion in 2025. It is expected to continue growing at a CAGR of 9.50%, reaching USD 54.88 billion by 2030.

Anticipating the Next Wave of Infectious Vaccine Innovation

The global landscape for infectious vaccines stands at a pivotal juncture, driven by accelerating scientific breakthroughs and evolving public health demands. A surge in advanced platform technologies has transformed the traditional paradigm, opening pathways to more precise, faster and scalable immunization approaches. As societies reckon with both established pathogens and emerging threats, the imperative to innovate has never been more profound.

This executive summary synthesizes critical insights across four transformative shifts reshaping research, regulatory frameworks, manufacturing and distribution. It examines the implications of projected United States tariffs on the vaccine supply chain, unpacks granular market segmentation dynamics, highlights regional patterns, profiles leading industry players and offers actionable guidance for decision-makers. By drawing on rigorous primary and secondary research, this overview equips executives with the intelligence needed to navigate risk, capture growth and drive impact in the dynamic infectious vaccines arena.

Emerging Transformations Redefining Vaccine Development and Deployment

Vaccine development and deployment are undergoing seismic reinvention, anchored by novel scientific modalities and infrastructural modernization. The ascent of mRNA and viral vector platforms has redefined antigen design, enabling accelerated candidate screening and bespoke immunogenic profiles. Concurrent progress in synthetic biology, adjuvant co-formulation and nanoparticle engineering further augments potency and durability, challenging legacy manufacturing conventions.

Regulatory authorities worldwide are streamlining dossier requirements and embracing rolling reviews to expedite conditional approvals during public health emergencies. At the same time, modular, flexible production facilities are gaining prominence, reducing capital intensity and facilitating rapid technology transfers. These lean models dovetail with contract development and manufacturing partnerships, which now play an indispensable role in scaling capacity without sacrificing quality.

On the distribution front, digital track-and-trace systems and next-generation cold-chain solutions are fortifying supply-chain resilience. Public-private coalitions are coalescing around mission-critical immunization goals, while integrated data platforms provide real-time visibility into stock levels and vaccination coverage. Together, these innovations are establishing a holistic, end-to-end ecosystem that prioritizes both speed and access.

Assessing the 2025 Tariff Impact on the US Vaccine Market

In 2025, the implementation of new United States tariffs on selected raw materials and finished vaccine imports will reverberate across the supply chain. Manufacturers dependent on overseas excipients may face elevated input costs, prompting reevaluation of global sourcing strategies. This policy shift underscores the need for near-shoring and supplier diversification to mitigate exposure to trade disruptions.

Distribution partners and end-user entities will need to adapt to potential price adjustments, requiring careful contract renegotiations and contingency planning. Organizations with vertically integrated operations are better positioned to absorb tariff impacts, while others may need to pursue collaborative agreements to secure preferred access and pricing. Public health agencies and nonprofit coalitions are likely to intensify advocacy for tariff exemptions on critical biologics to safeguard immunization campaigns.

Strategically, forward-looking companies are assessing the feasibility of establishing domestic fill-finish sites and exploring in-country licensing arrangements. By accelerating capacity expansion within the United States, stakeholders can insulate production timelines from cross-border cost fluctuations. Proactive engagement with regulators and policy makers will be vital to shaping equitable trade frameworks that sustain innovation incentives while protecting public health interests.

Deep-Dive into Vaccine Market Segmentation Drivers

A nuanced understanding of market segmentation reveals divergent growth vectors across vaccine platforms. Conjugate vaccines such as Hib conjugate, meningococcal conjugate and pneumococcal conjugate continue to earn strong demand due to their proven efficacy and integration into routine immunization schedules. Inactivated preparations addressing hepatitis A, influenza, polio and rabies sustain stable uptake, supported by well-established clinical profiles. Live attenuated offerings spanning influenza LAIV to measles, oral polio, rubella and varicella benefit from decades of trust, even as manufacturers refine formulations to enhance thermostability.

Advanced biologics such as lipid nanoparticle mRNA constructs and self-amplifying mRNA candidates are capturing investor attention with their rapid development cycles and adaptability to variant strains. Subunit strategies, including protein subunit and virus-like particle vaccines, are emerging as safer alternatives in populations with compromised immunity. Toxoid platforms targeting diphtheria, pertussis and tetanus uphold their status in combination regimens, while viral vector systems leveraging adenovirus backbones, MVA scaffolds and VSV frameworks expand the toolkit against novel pathogens.

Differences in route of administration influence market prioritization. Intradermal and intramuscular injections remain the default in mass campaigns, yet nasal sprays and oral formulations are gaining momentum for needle-averse populations. Subcutaneous delivery is also seeing renewed interest for its ease of use in decentralized settings.

On the demand side, clinics encompassing both general practice and specialty care drive routine vaccination, while hospitals-both private and public-play critical roles in outbreak response. Pharmacies delivered online and through retail networks have emerged as accessible points of care. Public health centers, whether in rural catchment areas or urban districts, continue to anchor immunization outreach. Distribution channels span local and national government agencies, in-hospital and outpatient pharmacy dispensaries, direct and platform-based online pharmacies, as well as chain and independent retail outlets. Each channel presents unique logistical requirements and partnership opportunities for market participants.

Regional Dynamics Shaping Global Vaccine Distribution

The Americas remain a focal point for commercial vaccine launches, fueled by robust R&D investment, streamlined regulatory pathways and a diverse network of public and private payers. Mature markets in North America demand advanced platforms and drive premium pricing models, while Latin American procurement agencies increasingly leverage pooled tenders to secure volume discounts and accelerate immunization coverage.

In Europe, Middle East & Africa, a complex mosaic of high-income and emerging economies shapes market access dynamics. European Union harmonization efforts streamline approval for central markets, even as national health agencies negotiate procurement terms. In the Middle East and Africa, capacity building and technology transfer initiatives are scaling local manufacturing, and donor-funded programs continue to be essential in expanding vaccine reach to underserved communities.

Asia-Pacific illustrates a dual narrative of manufacturing prowess and intensifying local demand. Governments in China, India and Southeast Asia are investing heavily in biotech infrastructure to transition from contract manufacturers to developers of proprietary vaccines. At the same time, public health drives in Australia, Japan and South Korea focus on next-generation immunogens, leveraging digital health platforms to optimize distribution and monitor safety in real time.

Competitive Landscape and Leading Vaccine Innovators

The competitive landscape in infectious vaccines features a blend of established pharmaceutical powerhouses and agile biotech innovators. Leading corporations actively leverage their scale to expand mRNA and viral vector portfolios, engaging in strategic alliances with research institutes to accelerate pipeline progression. Simultaneously, nimble midsize firms often specialize in differentiated adjuvants or novel delivery technologies, securing licensing deals with marquee partners.

Mergers and acquisitions remain a prominent strategy for market consolidation, enabling companies to absorb competing platforms and broaden therapeutic scopes. Joint ventures are fueling capacity expansions, particularly in regions seeking domestic fill-finish capabilities. Collaborations between multinational players and regional champions are catalyzing rapid commercial launches, supported by co-investment in manufacturing assets and shared regulatory expertise.

Innovation hubs in North America and Europe continue to lead in basic research, while Asia-Pacific clusters are emerging as hotbeds for clinical development and large-scale production. This distributed ecosystem encourages cross-border talent mobility and fosters a competitive rhythm that accelerates time to market. Industry leaders are harnessing these dynamics to strengthen their global foothold and advance next-generation vaccines from concept to clinic.

Strategic Imperatives for Capturing Market Opportunities

Industry leaders should prioritize strategic investment in advanced platform technologies, focusing not only on mRNA and viral vectors but also on emerging modalities such as self-amplification and nanoparticle-based systems. Cultivating partnerships with academic centers and specialty research firms will sustain a robust innovation pipeline and facilitate access to early-stage breakthroughs.

To enhance supply chain resilience, organizations must diversify their supplier base and explore regional manufacturing hubs that can mitigate the impact of trade policies and geopolitical risks. Strengthening cold-chain infrastructure through digital monitoring and automated tracking will minimize product losses and bolster stakeholder confidence.

Proactive engagement with regulatory authorities can expedite approval pathways, particularly during public health emergencies. Leaders should invest in dedicated teams to navigate evolving guidelines and contribute to harmonization efforts. Simultaneously, integrating real-world evidence platforms will generate compelling safety and efficacy data post-launch, reinforcing market positioning and supporting value-based contracting discussions.

Robust Methodological Approach Ensuring Research Rigor

This research rests on a structured multi-phase methodology that merges rigorous secondary intelligence with targeted primary validation. The process began with a comprehensive review of peer-reviewed journals, regulatory filings and patent databases to map the current vaccine landscape and identify emerging scientific trends.

Building on these insights, in-depth interviews were conducted with senior executives across vaccine developers, contract manufacturers, distribution partners and public health agencies. These conversations provided granular context around supply-chain vulnerabilities, go-to-market strategies and operational best practices.

All findings underwent triangulation through cross-referencing quantitative data from trade reports, clinical trial registries and government procurement records. A multi-disciplinary team of subject-matter experts continuously reviewed interim deliverables to ensure analytical integrity and strategic relevance. This integrated approach guarantees that recommendations are both evidence-based and aligned with real-world decision frameworks.

Synthesis of Insights Driving Strategic Decisions

This executive summary distills a wealth of qualitative and quantitative insights to inform strategic decision-making in the infectious vaccines domain. By examining technological breakthroughs, policy influences and market segmentation, stakeholders gain a panoramic view of current and emerging opportunities. The assessment of tariff implications offers clarity on potential cost pressures, while regional analysis underscores the distinct paths to growth across the globe.

Leading companies are competing on multiple fronts-scientific innovation, manufacturing agility and distribution excellence. The competitive landscape continues to evolve through partnerships and consolidation, emphasizing the importance of proactive collaboration. Actionable recommendations guide industry leaders on investment priorities, supply-chain diversification and regulatory engagement, equipping them to navigate complexity and capture value in a rapidly shifting environment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Conjugate
      • Hib Conjugate
      • Meningococcal Conjugate
      • Pneumococcal Conjugate
    • Inactivated
      • Hepatitis A
      • Influenza
      • Polio
      • Rabies
    • Live Attenuated
      • Influenza Laiv
      • Measles
      • Oral Polio
      • Rubella
      • Varicella
    • MRNA
      • Lipid Nanoparticle MRNA
      • Self-Amplifying MRNA
    • Subunit
      • Protein Subunit
      • Virus-Like Particle
    • Toxoid
      • Diphtheria
      • Pertussis
      • Tetanus
    • Viral Vector
      • Adenovirus
      • MVA
      • VSV
  • Route Of Administration
    • Intradermal
    • Intramuscular
    • Intranasal
    • Oral
    • Subcutaneous
  • End User
    • Clinics
      • General Practice
      • Specialty
    • Hospitals
      • Private
      • Public
    • Pharmacies
      • Online
      • Retail
    • Public Health Centers
      • Rural
      • Urban
  • Distribution Channel
    • Government Agencies
      • Local
      • National
    • Hospital Pharmacies
      • In-Hospital
      • Outpatient
    • Online Pharmacies
      • Direct
      • Platform
    • Retail Pharmacies
      • Chain
      • Independent
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Moderna, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • BioNTech SE
  • CSL Limited
  • Sinovac Biotech Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Infectious Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Conjugate
8.2.1. Hib Conjugate
8.2.2. Meningococcal Conjugate
8.2.3. Pneumococcal Conjugate
8.3. Inactivated
8.3.1. Hepatitis a
8.3.2. Influenza
8.3.3. Polio
8.3.4. Rabies
8.4. Live Attenuated
8.4.1. Influenza Laiv
8.4.2. Measles
8.4.3. Oral Polio
8.4.4. Rubella
8.4.5. Varicella
8.5. MRNA
8.5.1. Lipid Nanoparticle MRNA
8.5.2. Self-Amplifying MRNA
8.6. Subunit
8.6.1. Protein Subunit
8.6.2. Virus-Like Particle
8.7. Toxoid
8.7.1. Diphtheria
8.7.2. Pertussis
8.7.3. Tetanus
8.8. Viral Vector
8.8.1. Adenovirus
8.8.2. MVA
8.8.3. VSV
9. Infectious Vaccines Market, by Route of Administration
9.1. Introduction
9.2. Intradermal
9.3. Intramuscular
9.4. Intranasal
9.5. Oral
9.6. Subcutaneous
10. Infectious Vaccines Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. General Practice
10.2.2. Specialty
10.3. Hospitals
10.3.1. Private
10.3.2. Public
10.4. Pharmacies
10.4.1. Online
10.4.2. Retail
10.5. Public Health Centers
10.5.1. Rural
10.5.2. Urban
11. Infectious Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Government Agencies
11.2.1. Local
11.2.2. National
11.3. Hospital Pharmacies
11.3.1. in-Hospital
11.3.2. Outpatient
11.4. Online Pharmacies
11.4.1. Direct
11.4.2. Platform
11.5. Retail Pharmacies
11.5.1. Chain
11.5.2. Independent
12. Americas Infectious Vaccines Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Infectious Vaccines Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Infectious Vaccines Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Merck & Co., Inc.
15.3.3. GlaxoSmithKline plc
15.3.4. Sanofi S.A.
15.3.5. Moderna, Inc.
15.3.6. AstraZeneca plc
15.3.7. Johnson & Johnson
15.3.8. BioNTech SE
15.3.9. CSL Limited
15.3.10. Sinovac Biotech Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. INFECTIOUS VACCINES MARKET MULTI-CURRENCY
FIGURE 2. INFECTIOUS VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 123. CANADA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 124. CANADA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 125. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 126. CANADA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 127. CANADA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 128. CANADA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 129. CANADA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 130. CANADA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 131. CANADA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. CANADA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 134. CANADA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 135. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 137. CANADA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. CANADA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 139. CANADA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 140. CANADA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. CANADA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 144. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 145. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 146. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 147. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 148. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 149. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 150. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 238. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 239. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 240. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 241. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 242. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 243. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 244. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 245. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 246. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 252. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 254. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 257. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 258. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 259. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 260. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 261. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 262. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 263. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 264. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 265. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 270. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 271. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 273. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 281. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 282. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 283. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 284. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 287. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 289. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 290. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 292. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 294. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 295. ITALY INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 296. ITALY INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 297. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 298. ITALY INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 299. ITALY INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 300. ITALY INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 301. ITALY INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 302. ITALY INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 303. ITALY INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. ITALY INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. ITALY INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 308. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 309. ITALY INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. ITALY INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 311. ITALY INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 312. ITALY INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 313. ITALY INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 314. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 315. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 316. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 317. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 318. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 319. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 320. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 321. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 322. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 325. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 327. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2030 (USD MILLION)
TABLE 328. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 330. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 331. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 332. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 339. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2030 (USD MILLION)
TABLE 340. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILL

Companies Mentioned

The companies profiled in this Infectious Vaccines market report include:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Moderna, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • BioNTech SE
  • CSL Limited
  • Sinovac Biotech Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 34.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 54.88 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Infectious Vaccine Collaboration and Licensing Deals 2016-2025 - Product Image

Infectious Vaccine Collaboration and Licensing Deals 2016-2025

  • Report
  • 300 Pages
  • Global
From
Vaccines Market by Type, Vaccine Combination, Source, Vaccine Classification, Route of Administration, Indication, Age Group, End User - Global Forecast to 2030 - Product Image

Vaccines Market by Type, Vaccine Combination, Source, Vaccine Classification, Route of Administration, Indication, Age Group, End User - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From

About the Infectious Disease Vaccine Market

The Infectious Disease Vaccine market is a subset of the larger Infectious Diseases Drugs market. Vaccines are a form of preventive medicine, designed to protect individuals from contracting a particular infectious disease. Vaccines work by introducing a weakened or inactive form of the virus into the body, which stimulates the immune system to create antibodies that can fight off the virus if it is encountered in the future. Vaccines are typically administered through injection, but some are available in oral or nasal spray form. The Infectious Disease Vaccine market is highly competitive, with many companies developing and marketing vaccines for a variety of infectious diseases. Companies in the market include Merck, Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.